NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Shares of Viatris Inc. VTRS slipped 1.07% to $9.24 Wednesday, on what proved to be an all-around mixed trading session for ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its ...

Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ETCompany ParticipantsScott Smith - Chief ...

Viatris Inc. missed sales/EPS estimates with 2025 guidance showing challenges like a $385M EBITDA hit. Learn why experts ...

Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, mainly due to a worse-than-feared hit to sales from import restrictions on the drugmaker's manufacturing plant in ...

Viatris launches review, plans share buybacks. CEO outlines strategy for cost structure and remediation efforts.

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past two ...